Sona Nanotech Closes Private Placement Financing to Raise $1,643,750 in Gross Proceeds
Halifax, Nova Scotia--(Newsfile Corp. - September 24, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")...
Cancer
Sona Nanotech Closes Private Placement Financing to Raise $1,643,750 in Gross Proceeds
Halifax, Nova Scotia--(Newsfile Corp. - September 24, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")...
Tigerlily Foundation’s Annual Empower Ball: An Evening of Recognizing Impact in Health Equity, Empowerment and Transformation
WASHINGTON, DC / ACCESSWIRE / September 24, 2024 / Tigerlily Foundation proudly announces its Annual EmPOWER Ball, an evening dedicated...
Curium Announces the Official Opening its New Netherlands Facility for the Production of Lutetium-177 – a Game Changer Therapy Isotope for Cancer Patients Worldwide
Curium Opens New Lu-177 Production Facility, Transforming Cancer Treatment Curium project team with Kate Briant, Ciril Faia, Frank de Lange...
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within...
Starton Therapeutics’ Chief Executive Officer Chosen as 2024 Honoree by the Icla da Silva Foundation
PARAMUS, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming...
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease.An estimated one in 100 people...
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the...
Immutep Receives A$3.6 million R&D Tax Incentive from French Government
Media Release SYDNEY, AUSTRALIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”),...
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024NEW YORK and VIENNA, Sept. 24,...
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumorsLEXINGTON, Mass., Sept. 24,...
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
The agreement has been signed upon successful conclusion of a clinical study in dogs with osteoarthritis RAMAT GAN, Israel, Sept....
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company...
Oxford-Harrington Rare Disease Centre to Host Symposium on Pioneering Research and Innovation in Rare Disease Treatments
OXFORD, UK and CLEVELAND, Ohio, US, 24th September 2024 – The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the...
AlgoTx Announces “Last Patient Last Visit” in International Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy
PARIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing a first-in-class therapeutic for peripheral...
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — —...
LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy
Proceeds will be used to advance the Company’s IMANs into clinical trialsRaise underpins strong pre-clinical data demonstrating dual mechanism of...
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs...
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis
Toronto, Ontario--(Newsfile Corp. - September 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...
Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins
CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...